Jeremy Halpern

    Recent posts

  • 2014 Trends in Early-Stage Life Sciences Investment

    The Affordable Care Act has certainly made headlines over the past year—and the ACA, along with several other developments in the current venture funding environment, is beginning to radically reshape value... Read more »

  • Angels in Life Science America

    What happens when the FDA approval process slows down and imposes higher hurdles, when cost-reduction becomes central to the healthcare provider business model, when clinical trials and commercialization costs for medical... Read more »

Page 1 of 1